AstraZeneca (NYSE:AZN) and Merck (NYSE:MRK) announce that LYNPARZA demonstrated a long-term progression-free survival (PFS) benefit versus placebo as a 1st-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated (BRCAm) ovarian cancer who had a complete or partial response following platinum-based chemotherapy.
Five-year follow-up data from the Phase III SOLO-1 trial showed LYNPARZA reduced the risk of disease progression or death by 67% (based on a hazard ratio [HR] of 0.33; 95% confidence interval [CI] 0.25-0.43) and improved PFS to a median of 56.0 months versus 13.8 months for placebo.
At five years, 48.3% of patients treated with LYNPARZA remained free from disease progression versus 20.5% on placebo.
The median duration of treatment with LYNPARZA was 24.6 months versus 13.9 months with placebo.
The safety profile of LYNPARZA was consistent with previous observations. 12% of patients on LYNPARZA discontinued treatment due to an adverse events.
The results were presented on at the 2020 European Society of Medical Oncology (ESMO) virtual congress.
Shares are up 2% premarket.